If you want to distinguish your goods, services or both from those of another company, you may need a trademark or trade name. Find out what they are, what their registration procedure is and what it involves.
Information on the deadlines for filing applications for transformation of European Union trademarks into Spanish national trademarks. See more
If you have a new device, product or procedure that solves a technical problem or has a practical advantage, there are different ways to protect it in Spain and other countries. Find out how.
Does your innovation lie in the aesthetics, ornamentation or appearance of your product? Protect it through industrial design. Find out what rights registration confers and how to proceed.
Patents published worldwide are a valuable source of scientific, technical and commercial information.
El Bono 3 del Fondo para PYMEs 2025, que cubre la elaboración de Informes Tecnológicos de Patentes (ITP) y Búsquedas Retrospectivas se cerrará el lunes 10 de febrero de 2025 al cierre de la jornada laboral. Próximamente se informará sobre su reapertura. Puede consultar más información aquí.
If you are an entrepreneur or a company and you want to boost and improve the profitability of your business by adequately protecting the intangible assets of your organisation, in this space you will find what you need.
232
results.
Updated on
07/06/2025 [07:52:00]
Results 50 to 75 of 232
Absstract of: WO2025116176A1
The present invention relates to nanoparticles which comprise: a liposome core; a chitosan coating layer on the surface thereof; and bromelain bound to at least a part of chitosan of the chitosan coating layer, thereby facilitating mucus attachment and penetration and having excellent stability.
Absstract of: WO2025113255A1
The present invention provides a composite molecule, a nucleic acid, a vector, a host cell, and a pharmaceutical composition, and uses of the composite molecule, the nucleic acid, the vector, the host cell, and the pharmaceutical composition in preparation of drugs for treating cancers. The composite molecule comprises an anti-tumor antibody domain, a linker, and pro-IL-15; the anti-tumor antibody domain is linked to the pro-IL-15 by means of the linker; the anti-tumor antibody domain is a complete antibody against an immune checkpoint molecule, a tumor antigen molecule or an immune activation molecule, or a nano antibody or an antigen binding fragment thereof; the linker is a polypeptide linker or a non-peptide linker; the pro-IL-15 is a fusion protein comprising IL-15, an IL-15Rα sushi domain, and a linker peptide, and optionally comprising an IL-15Rβ extracellular domain; and the IL-15Rβ extracellular domain, the IL-15, and the IL-15Rα sushi domain are linked by means of the linker peptide.
Absstract of: WO2025112086A1
Disclosed are an oxidation-responsive cationic water-soluble pillararene, and a preparation method and a use. The oxidation-responsive water-soluble cationic pillararene is a cyclic small-molecule nucleic acid carrier and is obtained by carrying out quaternization reaction on 4-methyl borate and a tertiary amine modified pillararene. A delivery carrier having a high positive charge density is obtained by means of small molecule synthesis, the delivery carrier can tightly bind with a negatively-charged nucleic acid substance to form a nanocomposite, and after entering cells, in an oxidative environment, positive charges of the carrier fall off and the nucleic acid substance is released to efficiently express nucleic acid information.
Absstract of: WO2025113662A1
Provided are a lipid nanoparticle composition for delivering a nucleic acid drug, a preparation method therefor, and use thereof. The lipid nanoparticle composition comprises three lipid components: a steroid-cationic lipid compound, a neutral phospholipid, and a polyethylene glycol lipid. The composition prepared by mixing the described components has relatively good stability and transfection efficiency. The lipid nanoparticle is used for delivering nucleic acid, such as mRNA, can efficiently and stably deliver the nucleic acid drug to a target cell or organ, and can induce a relatively high specific antibody response in an experimental animal, and the antibody has a better safety profile.
Absstract of: US2025179096A1
Disclosed are an oxidation-responsive water-soluble cationic pillararene, and a preparation method and application thereof, the oxidation-responsive water-soluble cationic pillararene is a cyclic small-molecule nucleic acid vector, and is obtained by quaternization reaction of 4-methylborate and tertiary amine-modified pillararene. According to the invention, a delivery vector with a high positive charge density is obtained through small molecule synthesis, the delivery vector is capable of being tightly complexed with negatively charged nucleic acid substances to form a nano-composite, and after the nano-composite enters cells, vector positive charges fall off to release the nucleic acid substances in an oxidation environment, and nucleic acid is efficiently translated and expressed. The delivery vector has the characteristics of simplicity and convenience in synthesis, high delivery efficiency and good biological safety, and has a good application prospect.
Absstract of: US2025177423A1
Provided herein is a photoresponsive prodrug comprising an active agent conjugated to a photoresponsive group, and a nanoparticle, wherein the photoresponsive prodrug is co-assembled with a polymer to form a nanoparticle. Also provided is a method of treating a subject, comprising administering photoresponsive prodrug or the nanoparticle to the subject, and irradiating at the target site with a light source.
Absstract of: US2025177360A1
Disclosed are compositions and methods that provide pharmacodynamic effects specific to therapeutic macromolecules. The effects may result from reduced doses of therapeutic macromolecules in combination with immunosuppressant doses. The effects may also be enhanced with such compositions.
Absstract of: US2025177356A1
Long term storage stable bendamustine-containing compositions are disclosed. The compositions can include bendamustine or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable fluid which can include in some embodiments PEG, PG or mixtures thereof and an antioxidant or chloride ion source. The bendamustine-containing compositions have less than about 5% total impurities, on a normalized peak area response (“PAR”) basis as determined by high performance liquid chromatography (“HPLC”) at a wavelength of 223 nm, after at least about 15 months of storage at a temperature of from about 5° C. to about 25° C.
Absstract of: US2025177514A1
The present disclosure provides isolated immunogenic polypeptides comprising variant coronavirus spike proteins that are variants of a native coronavirus spike protein or fragment thereof, the variant coronavirus spike proteins having one or more modifications compared to the native coronavirus spike protein that: increase adoption by a receptor binding domain (RBD) of the variant coronavirus spike protein of an up conformation; and/or decrease adoption by a RBD of the variant coronavirus spike protein of a down conformation; and/or increase expression of the variant coronavirus spike protein compared to the native coronavirus spike protein; and/or increase adoption of a prefusion conformation; and/or decrease shedding of a S1 subunit of the variant coronavirus spike protein; and/or improve localization of the variant coronavirus spike protein to a host cell membrane. The present disclosure also provides compositions comprising the isolated immunogenic polypeptides and methods of making and using such compositions.
Absstract of: US2025177512A1
The present specification relates to vaccines comprising an mRNA polynucleotide encoding an antigen from an infectious microorganism; and an amphipathic cell penetrating RALA peptide.
Absstract of: US2025177503A1
The present invention relates to compositions comprising nanoparticles associated with or without one or more tolerogenic antigens, and compositions comprising an immunomodulatory agent (e.g., interleukin-2 (IL-2) or an IL-2 variant or an IL-2/IC)), and related methods involving co-administration of such compositions for purposes of inducing amplification of regulatory T cells (Tregs) (e.g., antigen-specific regulatory Tregs). The present invention further provides methods of treating autoimmune disorders through administering to a subject a composition comprising nanoparticles associated with or without one or more tolerogenic antigens associated with the autoimmune disorder prior to administering to the subject a composition comprising an immunomodulatory agent.
Absstract of: US2025177560A1
Functionalized nanoparticles for inhibiting or preventing pathogen infections (e.g., viral or bacterial infections, such as coronavirus infections) are described. The nanoparticles comprise a biodegradable polymer core and a lipid coating layer that is functionalized with a pathogen-binding receptor (e.g., an angiotensin-converting enzyme 2 (ACE2) receptor protein) and/or a pathogen-binding antibody or an antigen-binding fragment thereof (e.g., a virus-binding antibody or an antigen-binding fragment thereof). The nanoparticles are further functionalized by a phagocyte-specific ligand, e.g., a phosphatidylserine-containing lipid included in the lipid coating layer, to promote clearance of nanoparticle-bound pathogen. Methods of using the nanoparticles to treat or prevent pathogen infections (e.g., coronavirus infections) are also described.
Absstract of: US2025177556A1
Disclosed herein are methods and compositions related to delivery of pharmaceutical agents by lipid nanoparticles (LNPs) to a cell of a target organ (e.g., an eye, an ear) of a subject.
Absstract of: US2025177303A1
In various embodiments, drug delivery vehicles are provided for co-delivery of a chemotherapeutic agent and a TLR7/8 agonist and/or a lipoxin to a cancer. In certain embodiments the vehicles comprise a silicasome comprising: a porous nanoparticle encapsulated in a lipid bilayer, where the lipid bilayer contains a lipoxin and/or a lipid compatible TLR7/8 agonist disposed in the lipid bilayer, and the chemotherapeutic agent is contained in pores comprising the porous nanoparticle and the chemotherapeutic agent comprises a chemotherapeutic agent that induces immunogenic cell death (ICD); or a liposome comprising a lipid bilayer where the lipid bilayer contains a lipoxin and/or a lipid compatible a TLR7/8 agonist disposed in the lipid bilayer; and the chemotherapeutic agent is inside the liposome and the chemotherapeutic agent comprises a chemotherapeutic agent that induces immunogenic cell death (ICD).
Absstract of: US2025177532A1
The present invention relates to: a temperature-sensitive hydrogel for cancer treatment; a photothermal composition comprising the hydrogel as an active ingredient; and a preparation method for the temperature-sensitive hydrogel for cancer treatment. The temperature-sensitive hydrogel of the present invention includes gold nanostars as active ingredients, and thus can generate heat by light irradiation, thereby exhibiting a photothermal therapy effect. In addition, the hydrogel temperature increases so that the release of nitric oxide (NO) from S-nitrosocysteine can be induced. In addition, the temperature-sensitive hydrogel of the present invention includes S-nitrosocysteine as an active ingredient so that, upon a temperature rise due to a photothermal reaction, the penetration of drugs into a tumor site can be improved by the release of NO, and at the same time, apoptosis of cancer cells can be directly caused; and includes an immunotherapy agent as an active ingredient so that tumor size can be effectively suppressed even with the passage of time. Therefore, as a material that enables complex treatment combined with photothermal therapy and immunotherapy, the temperature-sensitive hydrogel of the present invention having the aforementioned effect can be usefully utilized in the field of medicine for cancer treatment.
Absstract of: US2025177558A1
Compositions, methods, and kits are provided for treating bacterial infections with nanoclusters comprising a metallic core conjugated to a nucleotide. Recalcitrant infections are often difficult to treat because of the presence of persister cells, a subpopulation of bacterial cells that is highly tolerant of traditional antibiotics. Persister cells are dormant, which makes them less susceptible to many antibiotics, which are designed to kill growing cells. Administration of nanoclusters comprising a nucleotide was found to be highly efficacious in eradicating persister cells and for treating infections for a broad range of bacterial species, including Gram-positive and Gram-negative bacteria. Such treatment was effective not only in eradicating planktonic bacteria but also bacteria in biofilms.
Absstract of: US2025179015A1
The present invention provides an ionizable lipid compound having an optimized carbon chain length and an amine head so that the ionizable lipid compound has increased delivery efficiency for an active molecule including, but not limited to, nucleic acids, proteins, small molecule drugs and the like. The present invention further relates to a lipid nanoparticle (LNP) comprising the ionizable lipid compound and the active molecule, and a pharmaceutical composition comprising the lipid nanoparticle.
Absstract of: US2025179034A1
One or more ionizable lipid(s) and lipid nanoparticles comprising same are provided. Pharmaceutical compositions comprising the lipid nanoparticles encapsulating an active agent are also provided.
Absstract of: US2025177479A1
An embodiment relates to a depsipeptide-based building block for inhibiting protein-protein interactions, a nanostructure including the same, and a use thereof, wherein the depsipeptide-based building block may remain in the body and cells for a long time when administered in vivo and be delivered to a target tissue with high efficiency, and a peptide for inhibiting protein-protein interactions may be gradually released over a long time to obtain a high effect.
Absstract of: WO2024026444A1
Non-invasive, in situ forming depots for delivery of a therapeutic agents, containing heterodimerizing, synthetic leucine zippers for physical crosslinking mediated by competition-based dimerization. The heterodimerizing, synthetic leucine zippers form a self-assembling depot of the therapeutic agent at a target site in vivo. A library of such heterodimerizing, synthetic leucine zippers is provided, as well as methods of treating subjects using the same.
Absstract of: AU2023313035A1
The invention concerns a novel and innovative composition for the treatment of neuropathic pain (NP). Specifically, the invention concerns HfO
Absstract of: EP4563142A1
The present invention relates to lipid nanoparticles capable of delivering a target substance to hepatic stellate cells. The lipid nanoparticles are for delivering a target substance to hepatic stellate cells and comprise a pH-sensitive cationic lipid including a hydrophilic portion and two hydrophobic portions, wherein an acid dissociation constant pKa of a lipid membrane constituting the lipid nanoparticles is greater than or equal to 6.7 and less than 8.2.
Absstract of: WO2024026029A2
Disclosed are compositions and methods related to lipid nanoparticles (LNPs) comprising ionizable lipids. The LNPs can comprise nucleic acid sequences encoding therapeutic peptides for immunotherapy, for example, bispecific antibodies or antigen binding fragments thereof.
Absstract of: CN119698325A
The present invention relates to microcapsules based on a polymeric shell and a lipophilic active core material with improved thermal stability.
Nº publicación: EP4561633A1 04/06/2025
Applicant:
4BASEBIO UK LTD [GB]
4basebio UK Ltd
Absstract of: WO2024023361A1
Nanoparticles suitable for delivery of a cargo to a chondrocyte, and targeting peptides comprising a chondrocyte targeting sequence, are provided. Further provided are uses of the nanoparticles and targeting peptides, for example, in treating a joint or cartilage disease or disorder.
BOPI
Electronic site
